NICK RAMANDI: Open Payments
NPI 1124219050 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,920 in 17 payments from 9 companies in 2025. Trend: 2023 $911 · 2024 $2,062 · 2025 $1,920
Food & beverage: $1,920
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $365 |
| Alkermes, Inc. | 3 | $306 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $242 |
| ABBVIE INC. | 2 | $240 |
| Axsome Therapeutics, Inc. | 2 | $234 |
| E.R. Squibb & Sons, L.L.C. | 2 | $215 |
| Collegium Pharmaceutical, Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $102 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $91 |
Products named: ABILIFY MAINTENA, CAPLYTA, VRAYLAR, Auvelity, COBENFY, Jornay PM, REXULTI, ARISTADA.
Industry payments across LA — which companies pay providers there.
